Special Issue

Topic: Resistance in Endocrine Therapy of Prostate Cancer

A Special Issue of Cancer Drug Resistance

ISSN 2578-532X (Online)

Submission deadline: 31 May 2020

Guest Editor(s)

Vincent C. O. Njar, Ph.D.
Professor of Medicinal Chemistry & Pharmacology, Dept. of Pharmacology;
Head, Medicinal Chemistry Section, Center for Biomolecular Therapeutics (CBT);
Member, Hormone Responsive Cancer Program, Marlene and Stewart Greenebaum Comprehensive Cancer Center;
University of Maryland School of Medicine;
Baltimore; MD, USA.

Special Issue Introduction

Prostate cancer is the second most frequently diagnosed cancer in men worldwide and it is the fifth leading cause of cancer-related death in men. Because the androgen receptor (AR) is the major target that drives this disease, endocrine therapies that modulate androgen receptor/androgen signaling, are the mainstay for the treatment of prostate cancer. These drugs are used for both castration-sensitive and castration-resistant disease states. Although endocrine therapy is the most widely used class of drugs for prostate cancer, a significant proportion of patients have innate resistance to the drugs and almost all patients eventually develop drug resistance. However, the mechanisms of resistance to these drugs are still emerging, mechanisms such as upregulation of AR, induction of AR point mutations, induction of AR splice variants, upregulation of 17α-hydroxylase/17.20-lyase (CYP17), a key enzyme in the steroidogenic pathway that lies at the crossroads of androgen and corticoid biosynthesis, upregulation of glucocorticoid receptor and activation of eukaryotic translation initiation factor 4F complex (eIF4F), a regulatory hub where several oncogenic hyperactive signaling pathways converge are well established. This Special Issue provides a comprehensive review of advances in these resistance mechanisms pathways/targets and the scientific and clinical progress to tackle this important medical problem and the challenges that are yet unmet.

Keywords

Prostate cancer, androgens, androgen receptor, endocrine therapies, hormonal/antihormonal therapies, castration, castration-resistant prostate cancer, drug resistance, molecular mechanisms of drug resistance

Submission Deadline

31 May 2020

Submission Information

For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=367
Submission Deadline: 31 May 2020
Contacts: Belinda Zhang, Assistant Editor, belinda@cdrjournal.com
Bill Li, Managing Editor, bill@cdrjournal.com

Published Articles

Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer

Open Access Review DOI: 10.20517/cdr.2020.54 18 Mar 2021
Views: Downloads:
Download PDF

Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators

Open Access Review DOI: 10.20517/cdr.2020.71 18 Mar 2021
Views: Downloads:
Download PDF

Intracrine androgen biosynthesis and drug resistance

Open Access Review DOI: 10.20517/cdr.2020.60 2 Nov 2020
Views: Downloads:
Download PDF

MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer

Open Access Review DOI: 10.20517/cdr.2020.30 11 Oct 2020
Views: Downloads:
Download PDF

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms

Open Access Review DOI: 10.20517/cdr.2020.45 16 Sep 2020
Views: Downloads:
Download PDF

Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways

Open Access Review DOI: 10.20517/cdr.2020.42 11 Sep 2020
Views: Downloads:
Download PDF

Molecular mechanisms of docetaxel resistance in prostate cancer

Open Access Review DOI: 10.20517/cdr.2020.37 20 Aug 2020
Views: Downloads:
Download PDF

Identification of sequence-specific interactions of the CD44-intracellular domain with RUNX2 in the transcription of matrix metalloprotease-9 in human prostate cancer cells

Open Access Original Article DOI: 10.20517/cdr.2020.21 20 Aug 2020
Views: Downloads:
Download PDF
Cancer Drug Resistance
ISSN 2578-532X (Online)
Follow Us

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/